Vera Hirsh

Vera Hirsh

UNVERIFIED PROFILE

Are you Vera Hirsh?   Register this Author

Register author
Vera Hirsh

Vera Hirsh

Publications by authors named "Vera Hirsh"

Are you Vera Hirsh?   Register this Author

88Publications

2393Reads

47Profile Views

Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer.

Oncologist 2019 May 28. Epub 2019 May 28.

Cross Cancer Institute and Department of Oncology, University of Alberta, Edmonton, Alberta, Canada.

View Article

Download full-text PDF

Source
http://theoncologist.alphamedpress.org/lookup/doi/10.1634/th
Publisher Site
http://dx.doi.org/10.1634/theoncologist.2019-0027DOI Listing
May 2019

Turning mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors.

Authors:
Vera Hirsh

Ther Adv Med Oncol 2018 22;10:1758834017753338. Epub 2018 Jan 22.

McGill Department of Oncology, Royal Victoria Hospital, Glen Site, 1001 Décarie Blvd, Montreal, QC H4A 3J1, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1758834017753338DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784552PMC
January 2018

Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge", Napoli, November 30th 2016.

J Transl Med 2017 10 11;15(1):205. Epub 2017 Oct 11.

Department of Urology and Gynecology, Istituto Nazionale Tumori "Fondazione G. Pascale", Naples, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12967-017-1309-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5637331PMC
October 2017

Long-term Outcomes of Induction Carboplatin and Gemcitabine Followed by Concurrent Radiotherapy With Low-dose Paclitaxel and Gemcitabine for Stage III Non-small-cell Lung Cancer.

Clin Lung Cancer 2017 09 1;18(5):565-571. Epub 2017 Mar 1.

Department of Radiation Oncology, McGill University Health Centre, Montreal, Quebec, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2017.02.003DOI Listing
September 2017

New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib.

Authors:
Vera Hirsh

Onco Targets Ther 2017 11;10:2513-2526. Epub 2017 May 11.

McGill Department of Oncology, Royal Victoria Hospital, Montreal, QC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S104177DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5436789PMC
May 2017

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treatment of Metastatic Non-Small Cell Lung Cancer, with a Focus on Afatinib.

Front Oncol 2017 16;7:97. Epub 2017 May 16.

Department of Oncology, McGill University Health Centre, Montreal, QC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2017.00097DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5432609PMC
May 2017

Pointed Progress in Second-Line Advanced Non-Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition.

J Clin Oncol 2016 05 16;34(14):1676-88. Epub 2016 Feb 16.

Barbara Melosky, British Columbia Cancer Agency, Vancouver Centre, Vancouver, British Columbia; Quincy Chu, Cross Cancer Institute and University of Alberta, Edmonton, Alberta; Rosalyn Juergens, McMaster University, Juravinski Cancer Centre, Hamilton; Natasha Leighl, Princess Margaret Hospital and University of Toronto; Deanna McLeod, Kaleidoscope Strategic, Toronto, Ontario; and Vera Hirsh, Montreal General Hospital, Royal Victoria Hospital, and McGill University, Montreal, Quebec, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.63.8049DOI Listing
May 2016

Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer.

J Clin Oncol 2015 Aug 13;33(24):2667-74. Epub 2015 Jul 13.

Giorgio Scagliotti and Silvia Novello, University of Turin, Orbassano, Torino; Adolfo Favaretto, Istituto Oncologico Veneto, Padova; Armando Santoro, Istituto Clinico Humanitas, Milan, Italy; Joachim von Pawel, Asklepios-Fachkliniken München-Gauting, Munich, Germany; Rodryg Ramlau, Poznań University of Medical Sciences, Poznań, Poland; Fabrice Barlesi, Aix Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille, France; Wallace Akerley, Huntsman Cancer Institute, Salt Lake City, UT; Sergey Orlov, St Petersburg State Medical University, St Petersburg, Russian Federation; David Spigel, Clinical Locations, Nashville, TN; Vera Hirsh, McGill University Health Centre, Montreal, Quebec; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Lecia V. Sequist, Massachusetts General Hospital, Boston; Jeffrey S. Ross, Foundation Medicine, Cambridge; Brian Schwartz, ArQule, Woburn, MA; Alan Sandler, Genentech, San Francisco, CA; and Qiang Wang, Reinhard von Roemeling, and Dale Shuster, Daiichi Sankyo, Edison, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.7317DOI Listing
August 2015

Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib.

Authors:
Vera Hirsh

BioDrugs 2015 Jun;29(3):167-83

McGill Department of Oncology, Royal Victoria Hospital, 687 Pine Avenue W., Montreal, QC, H3A 1A1, Canada,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40259-015-0130-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4488453PMC
June 2015

The treatment of metastatic non-small cell lung cancer in a new era of personalized medicine.

Authors:
Vera Hirsh

Front Oncol 2015 3;5:20. Epub 2015 Feb 3.

Department of Medical Oncology, McGill University Health Centre , Montreal, QC , Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2015.00020DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315106PMC
February 2015

Patient-reported outcomes and quality of life in PROFILE 1007: a randomized trial of crizotinib compared with chemotherapy in previously treated patients with ALK-positive advanced non-small-cell lung cancer.

J Thorac Oncol 2014 Nov;9(11):1625-33

*Department of Medical Oncology, Institute of Cancer Sciences, Manchester University, and Christie Hospital NHS Foundation Trust, Manchester, United Kingdom; †Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea; ‡Department of Thoracic Oncology, Institut Gustave Roussy, Villejuif, France; §National Cancer Center Hospital, Tokyo, Japan; ‖Division of Translational & Clinical Research, Center for Lung Cancer, National Cancer Center, Goyang, South Korea; ¶Clinical Development, Pfizer Oncology, La Jolla, CA; #Biostatistics, Pfizer Global Innovative Pharma Business, New York, NY; **Global Outcomes & Evidence, Pfizer Oncology, New York, NY; ††Department of Oncology, McGill University Health Centre, Montreal, Canada; and ‡‡Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000318DOI Listing
November 2014

Management of Common Toxicities in Metastatic NSCLC Related to Anti-Lung Cancer Therapies with EGFR-TKIs.

Front Oncol 2014 16;4:238. Epub 2014 Sep 16.

Department of Medical Oncology, McGill University Health Centre, Royal Victoria Hospital , Montreal, QC , Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2014.00238DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4165207PMC
October 2014

Chemotherapy in Metastatic NSCLC - New Regimens (Pemetrexed, Nab-Paclitaxel).

Front Oncol 2014 21;4:177. Epub 2014 Jul 21.

McGill University Health Centre (MUHC), Royal Victoria Hospital , Montreal, QC , Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2014.00177DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4104641PMC
August 2014

Targeted treatments of bone metastases in patients with lung cancer.

Authors:
Vera Hirsh

Front Oncol 2014 16;4:146. Epub 2014 Jun 16.

McGill University Health Centre, Royal Victoria Hospital , Montreal, QC , Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2014.00146DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4058774PMC
July 2014

Is the Evaluation of Quality of Life in NSCLC Trials Important? Are the Results to be Trusted?

Authors:
Vera Hirsh

Front Oncol 2014 3;4:173. Epub 2014 Jul 3.

Department of Medical Oncology, McGill University Health Centre, Royal Victoria Hospital , Montreal, QC , Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2014.00173DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4080131PMC
July 2014

nab-paclitaxel for the management of patients with advanced non-small-cell lung cancer.

Authors:
Vera Hirsh

Expert Rev Anticancer Ther 2014 Feb;14(2):129-41

Royal Victoria Hospital and Montreal General Hospital, McGill University, Montreal, Quebec, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14737140.2014.881719DOI Listing
February 2014

Patient-reported neuropathy and taxane-associated symptoms in a phase 3 trial of nab-paclitaxel plus carboplatin versus solvent-based paclitaxel plus carboplatin for advanced non-small-cell lung cancer.

J Thorac Oncol 2014 Jan;9(1):83-90

*McGill University, Montreal, Quebec, Canada; †Kinki University Faculty of Medicine, Osaka-Sayama, Japan; ‡Clearview Cancer Institute, Huntsville, Alabama; §The Center for Cancer and Blood Disorders, Fort Worth, Texas; ‖Essex Oncology of New Jersey, Belleville, New Jersey; ¶Saitama Cancer Center, Saitama, Japan; #Celgene Corporation, Summit, New Jersey; and **University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000011DOI Listing
January 2014

Randomized, double-blind, phase II trial comparing gemcitabine-cisplatin plus the LTB4 antagonist LY293111 versus gemcitabine-cisplatin plus placebo in first-line non-small-cell lung cancer.

J Thorac Oncol 2014 Jan;9(1):126-31

*Department of Medical Oncology, Dana-Farber Cancer Institute and Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts; †IBIS (Virgen del Rocio Hospital, Seville University & CSIC), Seville, Spain; ‡Cancer Care Center of Frederick, Frederick, Maryland; §Asklepios Klinik Harburg, Hamburg, Germany; ‖Royal Victoria Hospital, Division of Medical Oncology, Montreal, Canada; ¶Eli Lilly and Company, Indianapolis, Indiana; and #Asklepios Klinikum Gauting, Munich, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000037DOI Listing
January 2014

Are the data on quality of life and patient reported outcomes from clinical trials of metastatic non-small-cell lung cancer important?

Authors:
Vera Hirsh

World J Clin Oncol 2013 Nov;4(4):82-4

Vera Hirsh, Division of Medical Oncology, McGill University Health Center, Quebec H3G 1A4, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5306/wjco.v4.i4.82DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4053709PMC
November 2013

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

J Clin Oncol 2013 Sep 1;31(27):3327-34. Epub 2013 Jul 1.

Lecia V. Sequist, Massachusetts General Hospital and Harvard Medical School, Boston, MA; James Chih-Hsin Yang, National Taiwan University Hospital; Chun-Ming Tsai, Taipei Veterans General Hospital, Taipei; Wu-Chou Su, National Cheng Kung University Hospital, Tainan, Taiwan; Nobuyuki Yamamoto, Shizuoka Cancer Center, Shizuoka; Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Kenneth O'Byrne, St James' Hospital, Dublin, Ireland; Vera Hirsh, McGill University, Montreal, Quebec, Canada; Tony Mok, Prince of Wales Hospital, Hong Kong, China; Sarayut Lucien Geater, Songklanagarind Hospital, Songkla, Thailand; Sergey Orlov, Pavlov State Medical University, St Petersburg; Vera Gorbunova, GU Russian Oncological Research Centre, Moscow, Russia; Michael Boyer, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia; Jaafar Bennouna, Institut de Cancérologie de l'Ouest-site René Gauducheau, Nantes, France; Ki Hyeong Lee, Chungbuk National University Hospital, Cheongju, South Korea; Riyaz Shah, Maidstone and Tunbridge Wells National Health Service Trust, Maidstone Hospital, Maidstone; Dan Massey, Victoria Zazulina, and Mehdi Shahidi, Boehringer Ingelheim, Bracknell, United Kingdom; and Martin Schuler, West German Cancer Center, University of Duisburg-Essen, Essen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.44.2806DOI Listing
September 2013

Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.

J Clin Oncol 2013 Sep 1;31(27):3342-50. Epub 2013 Jul 1.

James Chih-Hsin Yang, National Taiwan University Hospital, Taipei, Taiwan; Vera Hirsh, McGill University, Montreal, Quebec, Canada; Martin Schuler, West German Cancer Center, University Duisburg-Essen, Essen; Juliane Lungershausen, Boehringer Ingelheim GmbH, Ingelheim, Germany; Nobuyuki Yamamoto, Shizuoka Cancer Center, Shizuoka, Japan; Kenneth J. O'Byrne, St James' Hospital, Dublin, Ireland; Tony S.K. Mok, State Key Laboratory of Southern China, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong; Victoria Zazulina, Mehdi Shahidi, and Dan Massey, Boehringer Ingelheim Limited, Bracknell; Michael Palmer, Keele University, Keele, United Kingdom; and Lecia V. Sequist, Massachusetts General Hospital and Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.46.1764DOI Listing
September 2013

Saudi Lung Cancer Guidelines Supplement 2012. Introduction from the Guest Editor.

Authors:
Vera Hirsh

J Infect Public Health 2012 Dec 6;5 Suppl 1:S2-3. Epub 2012 Nov 6.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jiph.2012.09.006DOI Listing
December 2012

Saudi Lung Cancer Guidelines Supplement 2012. Conclusion.

Authors:
Vera Hirsh

J Infect Public Health 2012 Dec 6;5 Suppl 1:S61. Epub 2012 Nov 6.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jiph.2012.09.007DOI Listing
December 2012

An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastases.

Lung Cancer 2012 Oct 9;78(1):1-7. Epub 2012 Aug 9.

Hematology/Oncology Division, Oregon Health Sciences University, Portland, OR 97239, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2012.07.004DOI Listing
October 2012

Could targeting bone delay cancer progression? Potential mechanisms of action of bisphosphonates.

Crit Rev Oncol Hematol 2012 May 17;82(2):233-48. Epub 2011 Jun 17.

Department of Surgery, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S104084281100156
Publisher Site
http://dx.doi.org/10.1016/j.critrevonc.2011.05.009DOI Listing
May 2012

Denosumab will play an important role in patients with solid tumours and bone metastases.

Authors:
Vera Hirsh

Ann Palliat Med 2012 Apr;1(1):83

Lung cancer committee, McGill University, Royal Victoria hospital, 687 Pine Ave, West, Montreal, Quebec H3A 1A1, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2224-5820.2012.03.03DOI Listing
April 2012

Bisphosphonates: prevention of bone metastases in lung cancer.

Recent Results Cancer Res 2012 ;192:93-108

Department of Pulmonology, University Hospital Gasthuisberg, Leuven, Belgium.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/978-3-642-21892-7_4
Publisher Site
http://dx.doi.org/10.1007/978-3-642-21892-7_4DOI Listing
March 2012

Bisphosphonates in lung cancer: can they provide benefits beyond prevention of skeletal morbidity?

Authors:
Vera Hirsh

Anticancer Agents Med Chem 2012 Feb;12(2):137-43

Departments of Medicine and Oncology, McGill University Health Centre, Royal Victoria Hospital, 687 Pine Avenue West, Montreal, Quebec H3A 1A1, Canada.

View Article

Download full-text PDF

Source
February 2012

Second-line erlotinib in an EGFR mutation-negative patient with non-small-cell lung cancer.

Authors:
Vera Hirsh

Curr Oncol 2012 Feb;19(1):21-2

Medical Oncology Department, MUHC Royal Victoria Hospital, 687 Pine Avenue West, Suite A3.04, Montreal, Quebec H3A 1A1,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.19.959DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3267586PMC
February 2012

Emerging anticancer effects of antiresorptive therapies.

Authors:
Vera Hirsh

Anticancer Agents Med Chem 2012 Feb;12(2):94

View Article

Download full-text PDF

Source
February 2012

Authors:
Vera Hirsh

Anticancer Agents Med Chem 2011 Aug 17. Epub 2011 Aug 17.

Departments of Medicine and Oncology, McGill University Health Centre, Royal Victoria Hospital, Room A2.04, 687 Pine Avenue West, Montreal, Quebec H3A 1A1, Canada.

View Article

Download full-text PDF

Source
August 2011

Afatinib (BIBW 2992) development in non-small-cell lung cancer.

Authors:
Vera Hirsh

Future Oncol 2011 Jul;7(7):817-25

McGill University, Department of Medicine & Oncology, Royal Victoria Hospital, Montreal, Quebec, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon.11.62DOI Listing
July 2011

Review of the treatment of metastatic non small cell lung carcinoma: A practical approach.

Authors:
Vera Hirsh

World J Clin Oncol 2011 Jun;2(6):262-71

Vera Hirsh, Department of Medical Oncology, McGill University Health Centre, Royal Victoria Hospital, Montreal, QC H3A 1A1, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5306/wjco.v2.i6.262DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3139036PMC
June 2011

Zoledronic acid use in cancer patients: more than just supportive care?

Cancer 2011 Jan;117(1):11-23

Cancer Research Centre, University of Sheffield, Weston Park Hospital, Sheffield, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.25529DOI Listing
January 2011

Encouraging data out of the 2010 Congress of the European Society for Medical Oncology with respect to non-small-cell lung cancer.

Authors:
Vera Hirsh

Curr Oncol 2010 Nov;17(6):7-8

Associate Professor, Departments of Medicine and Oncology, McGill University, Chair, Lung Cancer Committee, McGill University, Chair, Lung Administrative Tumor Group, McGill University Health Centre ( muhc ), muhc Royal Victoria Hospital, Department of Medical Oncology, A3.04 - 687 Pine Avenue West, Montreal, Quebec H3A 1A1,

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2993445PMC
http://dx.doi.org/10.3747/co.v17i6.795DOI Listing
November 2010

Bisphosphonates in lung cancer: more than a palliative therapy?

Semin Oncol 2010 Jun;37 Suppl 1:S45-52

Boca Raton Comprehensive Cancer Center, FL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2010.06.004DOI Listing
June 2010

Skeletal morbidity in lung cancer patients with bone metastases: demonstrating the need for early diagnosis and treatment with bisphosphonates.

Lung Cancer 2010 Jan;67(1):4-11

Hematology-Oncology Division, University of Pennsylvania, 3400 Civic Center Blvd., 2 Perelman Center for Advanced Medicine, Philadelphia, PA 19104, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2009.08.020DOI Listing
January 2010

Skeletal disease contributes substantially to morbidity and mortality in patients with lung cancer.

Authors:
Vera Hirsh

Clin Lung Cancer 2009 Jul;10(4):223-9

McGill University Health Centre, Montreal, Quebec, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CLC.2009.n.030DOI Listing
July 2009

Emerging safety data for bevacizumab in advanced non-small-cell lung cancer.

Authors:
Vera Hirsh

Clin Lung Cancer 2008 Mar;9 Suppl 2:S62-70

McGill University Health Centre, Montreal, Quebec, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CLC.2008.s.010DOI Listing
March 2008

Docetaxel and Gemcitabine administered on days 1 and 8 for metastatic non-small cell lung carcinoma (NSCLC): a phase II multicenter trial.

Lung Cancer 2004 Oct;46(1):113-8

Medical Oncology Division, Room A2.04, Royal Victoria Hospital, McGill University, 687 Pine Avenue West, Montreal, Quebec, Canada H3A 1A1.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2004.03.007DOI Listing
October 2004